Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Boyang, Chang"'
Publikováno v:
Frontiers in Molecular Biosciences, Vol 10 (2023)
Background: Hepatocellular carcinoma (HCC) is extremely malignant and difficult to treat. The adenoviral early region 2 binding factors (E2Fs) target pathway is thought to have a major role in tumor growth. This study aimed to identify a predictive E
Externí odkaz:
https://doaj.org/article/37ce641b5c3e43bcb4a6af88dbd5216d
Autor:
Jun Dong, Shaofei Yuan, Boyang Chang, Jinsheng Huang, Xiaojing Geng, Xiuyu Cai, Pili Hu, Bei Zhang, Liangping Xia, Peihong Wu
Publikováno v:
Cancer Imaging, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background Thymoma is a rare tumor that originates from thymic epithelial cells and is usually associated with myasthenia gravis. Radiofrequency ablation (RFA) is a minimally invasive and curative treatment for other tumors, but RFA has not
Externí odkaz:
https://doaj.org/article/eaf2a589e20e4a9f881752149f5f9f07
Autor:
Lujun Shen, Qi Zeng, Pi Guo, Jingjun Huang, Chaofeng Li, Tao Pan, Boyang Chang, Nan Wu, Lewei Yang, Qifeng Chen, Tao Huang, Wang Li, Peihong Wu
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-10 (2018)
Patients with hepatocellular carcinoma require regular follow-up. Here, using Cox-based feature selection to identify key prognostic features, the authors convert time-series follow-up data into a cascading survival map, and show that the approach im
Externí odkaz:
https://doaj.org/article/da859ea395f4437b8d38707d5828dc84
Autor:
Ying Gao, Xueping Zheng, Boyang Chang, Yujie Lin, Xiaodan Huang, Wen Wang, Shirong Ding, Weixiang Zhan, Shang Wang, Beibei Xiao, Lanqing Huo, Youhui Yu, Yilin Chen, Run Gong, Yuanzhong Wu, Ruhua Zhang, Li Zhong, Xin Wang, Qiuyan Chen, Song Gao, Zhengfan Jiang, Denghui Wei, Tiebang Kang
Publikováno v:
Cell Research. 32:1086-1104
STING, an endoplasmic reticulum (ER) transmembrane protein, mediates innate immune activation upon cGAMP stimulation and is degraded through autophagy. Here, we report that activated STING could be transferred between cells to promote antitumor immun
Autor:
Yuan Gao, Su Li, Dazhi Xu, Shangxiang Chen, Yuchen Cai, Wenqi Jiang, Xinke Zhang, Jin Sun, Kefeng Wang, Boyang Chang, Fenghua Wang, Minghuang Hong
Publikováno v:
Chinese Journal of Cancer, Vol 36, Iss 1, Pp 1-14 (2017)
Abstract Background Anti-programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) immunotherapy has been proved to be effective on gastric cancer in ongoing clinical trials. However, the value of PD-L1 in predicting responses of patients with gastri
Externí odkaz:
https://doaj.org/article/708e1f4fbf2d4ce591e3f3c76c34cf96
Publikováno v:
Translational Cancer Research
Background Biomarkers in serum may have important clinical implications for personalized medicine, including therapeutic guidance, and monitoring of recurrence. The role of programmed cell death ligand 1 (PD-L1) expression as a tumor biomarker remain
Autor:
Jiesheng Qian, Yanyang Zhang, Duo Zhu, Zhaolin Zeng, Kangdi Zheng, Wenjie Mei, Luwen Mu, Tao Pan, Mingjun Bai, Qiang Xie, Shouhai Guan, Boyang Chang, Wenjie Tang
Publikováno v:
Journal of Coordination Chemistry. 72:2050-2064
Two new ruthenium(II) complexes, [Ru(bpy)2(DClPIP)](ClO4)2 (1) and [Ru(phen)2(DClPIP)](ClO4)2 (2) (bpy = 2,2′-bipyridine, phen = 1,10-phenanthroline, and DClPIP = 2-(2,4-dichlorophenyl)-1H-...
Publikováno v:
BioMed Research International, Vol 2019 (2019)
BioMed Research International
BioMed Research International
Objective. The aim of this study was to assess muscle injury associated with upper and lower closed limb fracture using ultrasound, and to develop ultrasound classification criteria for muscle injury. Patients and Methods. Thirty patients with limb f
Autor:
Shouhai Guan, Jiesheng Qian, Luwen Mu, Boyang Chang, Qiang Xie, Mingjun Bai, Gengnan Yu, Duo Zhu, Zhaolin Zeng, Wenjie Mei, Tao Pan, Yanyang Zhang
Publikováno v:
European Journal of Pharmacology. 853:49-55
Chiral ruthenium(II) complexes have long been considered as potential anticancer agents. Herein, in vivo inhibitory activity of a chiral ruthenium(II) complex coordinated by ligand 2-(2′-trifluoromethyphenyl) imidazo [4,5-f][1,10]phenanthroline, Δ
Autor:
Peihong Wu, Duo Zhu, Wenjun He, Tao Huang, Boyang Chang, Huajun Wei, Huihua Zhang, Ruopan Huang, Lujun Shen, Qifeng Chen, Yunjian Li, Wang Li
Publikováno v:
Cancer Immunology, Immunotherapy
Background Blocking the programmed death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway in hepatocellular carcinoma (HCC) is a very promising approach in immunotherapy. However, the correlation and prognostic values of serum soluble PD-1